EPHA7 haploinsufficiency is associated with a neurodevelopmental disorder.


Journal

Clinical genetics
ISSN: 1399-0004
Titre abrégé: Clin Genet
Pays: Denmark
ID NLM: 0253664

Informations de publication

Date de publication:
10 2021
Historique:
revised: 21 06 2021
received: 27 11 2020
accepted: 23 06 2021
pubmed: 28 6 2021
medline: 1 2 2022
entrez: 27 6 2021
Statut: ppublish

Résumé

Ephrin receptor and their ligands, the ephrins, are widely expressed in the developing brain. They are implicated in several developmental processes that are crucial for brain development. Deletions in genes encoding for members of the Eph/ephrin receptor family were reported in several neurodevelopmental disorders. The ephrin receptor A7 gene (EPHA7) encodes a member of ephrin receptor subfamily of the protein-tyrosine kinase family. EPHA7 plays a role in corticogenesis processes, determines brain size and shape, and is involved in development of the central nervous system. One patient only was reported so far with a de novo deletion encompassing EPHA7 in 6q16.1. We report 12 additional patients from nine unrelated pedigrees with similar deletions. The deletions were inherited in nine out of 12 patients, suggesting variable expressivity and incomplete penetrance. Four patients had tiny deletions involving only EPHA7, suggesting a critical role of EPHA7 in a neurodevelopmental disability phenotype. We provide further evidence for EPHA7 deletion as a risk factor for neurodevelopmental disorder and delineate its clinical phenotype.

Identifiants

pubmed: 34176129
doi: 10.1111/cge.14017
doi:

Substances chimiques

Receptor, EphA7 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

396-404

Informations de copyright

© 2021 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd.

Références

Himanen JP. Ectodomain structures of Eph receptors. Semin Cell Dev Biol. 2012;23:35-42.
Cramer KS, Miko IJ. Eph-ephrin signaling in nervous system development. F1000Research. 2016;5:1-8.
Kania A, Klein R. Mechanisms of ephrin - Eph signalling in development, physiology and disease. Nat Rev Mol Cell Biol. 2016;17:240-256.
Reddy S, Dolzhanskaya N, Krogh J, Velinov M. A novel 1.4 Mb de novo microdeletion of chromosome 1q21.3 in a child with microcephaly, dysmorphic features and mental retardation. Eur J Med Genet. 2009;52:443-445.
Lévy J, Haye D, Marziliano N, et al. EFNB2 haploinsufficiency causes a syndromic neurodevelopmental disorder. Clin Genet. 2018;93:1141-1147.
Traylor RN, Fan Z, Hudson B, et al. Microdeletion of 6q16.1 encompassing EPHA7 in a child with mild neurological abnormalities and dysmorphic features: case report. Mol Cytogenet. 2009;2:1-6.
Gale NW, Holland SJ, Valenzuela DM, et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis known family of RTKs with at least 13 distinct members family display dynamic and spatially restricted expres. Neuron. 1996;17:9-19.
Beuter S, Ardi Z, Horovitz O, et al. Receptor tyrosine kinase EphA7 is required for interneuron connectivity at specific subcellular compartments of granule cells. Sci Rep. 2016;6:1-15.
Clifford MA, Athar W, Leonard CE, et al. EphA7 signaling guides cortical dendriticdevelopment and spine maturation. Proc Natl Acad Sci U S A. 2014;111:4994-4999.
Engwerda A, Frentz B, den Ouden AL, et al. The phenotypic spectrum of proximal 6q deletions based on a large cohort derived from social media and literature reports. Eur J Hum Genet. 2018;26:1478-1489.
Morris CA. Williams syndrome summary genetic counseling. In Adam MP, Ardinger HH, Pagon RA, (Eds.). GeneReviews®. Seattle, WA: University of Washington; 2017;1-29. https://www.ncbi.nlm.nih.gov/books/NBK1249/.
Mirzaa GM, Chong JX, Piton A, et al. De novo and inherited variants in ZNF292 underlie a neurodevelopmental disorder with features of autism spectrum disorder. Genet Med. 2020;22:538-546. https://doi.org/10.1038/s41436-019-0693-9
Huang N, Lee I, Marcotte EM, Hurles ME. Characterising and predicting haploinsufficiency in the human genome. PLoS Genet. 2010;6:1-11.
Gerstmann K, Zimmer G. The role of the Eph / ephrin family during cortical development and cerebral malformations. Med Res Arch. 2018;6:1-26.
Leonard CE, Baydyuk M, Stepler MA, Burton DA, Donoghue MJ. EphA7 isoforms differentially regulate cortical dendrite development. PLoS One. 2020;15:e0231561.

Auteurs

Jonathan Lévy (J)

Genetics Department, APHP, Robert-Debré University Hospital, Paris, France.

Bérénice Schell (B)

Genetics Department, APHP, Robert-Debré University Hospital, Paris, France.

Hala Nasser (H)

Genetics Department, APHP, Robert-Debré University Hospital, Paris, France.

Myriam Rachid (M)

Genetics Department, APHP, Robert-Debré University Hospital, Paris, France.

Lyse Ruaud (L)

Genetics Department, APHP, Robert-Debré University Hospital, Paris, France.
Université de Paris Medical School, Paris, France.
INSERM UMR1141, Paris University, APHP, Robert-Debré Hospital, Paris, France.

Nathalie Couque (N)

Genetics Department, APHP, Robert-Debré University Hospital, Paris, France.

Patrick Callier (P)

Centre de Génétique et Centre de référence "Anomalies du Développement et Syndromes Malformatifs", Hôpital d'Enfants, Centre Hospitalier Universitaire de Dijon, Dijon, France.
Laboratoire de Génétique Chromosomique et Moléculaire, Plateau Technique de Biologie, Centre Hospitalier Universitaire de Dijon, Dijon, France.
UMR-Inserm 1231 GAD Team, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.

Laurence Faivre (L)

Centre de Génétique et Centre de référence "Anomalies du Développement et Syndromes Malformatifs", Hôpital d'Enfants, Centre Hospitalier Universitaire de Dijon, Dijon, France.
UMR-Inserm 1231 GAD Team, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.

Nathalie Marle (N)

Laboratoire de Génétique Chromosomique et Moléculaire, Plateau Technique de Biologie, Centre Hospitalier Universitaire de Dijon, Dijon, France.
UMR-Inserm 1231 GAD Team, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.

Aafke Engwerda (A)

Department of Genetics, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

Conny M A van Ravenswaaij-Arts (CMA)

Department of Genetics, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

Morgane Plutino (M)

Service de Génétique Médicale, Centre Hospitalier Universitaire de Nice, Nice, France.

Houda Karmous-Benailly (H)

Service de Génétique Médicale, Centre Hospitalier Universitaire de Nice, Nice, France.

Caroline Benech (C)

Etablissement Français du Sang, Brest, France.

Sylvia Redon (S)

Laboratoire de Génétique Moléculaire et Histocompatibilité, Service de Génétique Médicale, CHRU, Brest, France.

Odile Boute (O)

CHU Lille, Clinique de Génétique "Guy Fontaine", Lille, France.

Elise Boudry Labis (E)

CHU Lille, Institut de Génétique Médicale, Lille, France.

Mélanie Rama (M)

CHU Lille, Institut de Génétique Médicale, Lille, France.

Paul Kuentz (P)

UMR-Inserm 1231 GAD Team, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.
Génétique Biologique, PCBio, Centre Hospitalier Universitaire de Besançon, Besançon, France.

Jessica Assoumani (J)

Clinical Investigation Center 1431, INSERM, Besançon, France.

Lionel Van Maldergem (LV)

Clinical Investigation Center 1431, INSERM, Besançon, France.
Center of Human Genetics, University of Franche-Comté, Besançon, France.

Céline Dupont (C)

Genetics Department, APHP, Robert-Debré University Hospital, Paris, France.

Alain Verloes (A)

Genetics Department, APHP, Robert-Debré University Hospital, Paris, France.
Université de Paris Medical School, Paris, France.
INSERM UMR1141, Paris University, APHP, Robert-Debré Hospital, Paris, France.

Anne-Claude Tabet (AC)

Genetics Department, APHP, Robert-Debré University Hospital, Paris, France.
Neuroscience Department, Human Genetics and Cognitive Function Unit, Pasteur Institute, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH